Hoechst Aktiengesellschaft

Piramal Life Sciences Limited

Aventis Pharma Deutschland, Gmbh

Piramal Healthcare Limited

Hoeschst Aktiengesellschaft

Nicholas Piramal India Limited

Pirimal Life Sciences Ltd.

Piramal Life Science Limited

Bansi Lal

Jurgen Blumbach

Richard H Rupp

Swati Bal-Tembe

Noel J De Souza

Alihussein N Dohadwalla

Ravindra Dattatraya Gupte

Horst Dornauer

Usha Ghosh

Tulsidas More

Kalpana Sanjay Joshi

Aftab Dawoodbhai Lakdawala

Asha Adrian Kulkarni-Almeida

Malcolm Mascarenhas

Radha Bhaskar Panicker

Ramachandra Ganapati Naik

Rajendrakumar Joshi

Maggie Joyce Rathos

Shrikant Kamble

Sanjeev Kulkarni

Heinrich Christian Englert

Hans Jochen Lang

Robert R Bartlett

Klaus U Weithmann

Sapna Parikh

Ashok Kumar Gangopadhyay

Bindumadhavan Venugopalan

Yatendra Khandelwal

Vijay A Aroskar

Mandakini V Shirole

Vilas Narayan Mumbaikar

Anil Vasantrao Ghate

Arun Kumar Jain

Andreas Gerhard Weichert

Joachim Brendel

Wolfgang Scholz

Jan-Robert Schwark

Somesh Sharma

Bani K Bhattacharya

Dipak K Chatterjee

Adolf D'Sa

Vadlamudi V S V Rao

Anagha Suhas Kulkarni

Ramanujam Rajagopalan

Rangarajan Vasumathy

Rao Venkata Vadlamudi

Anagha Damre

Chintamani P Bapat

Pravin J Karnik

Gopal Vishnu Gole

Sridevi Krishnan

Eleanor Pinto De Souza

Pravin Gagare

Sunil Jadhav

Shashikant Patil

Ramanujam Rajgopalan

Hans-Jochen Lang

Heinz-Werner Kleemann

Martin Bickel

Udo Albus

Gerhard Dickneite

Hans H Sedlacek

Meenakshi Sivakumar

Heinz-Werner Kleeman

Nandkumar K Dadkar

Ramchandra G Naik

Satish Namdeo Sawant

Noel J deSouza

Ramesh Gidwani

Radha Panicker

Nirogi Venkata Ramakrishna

Chinnakulandai Sankar

Alihussein Nomanbhai Dohadwalla, Deceased

Narayan Sudhindra Punekar

Julius Mascarenhas

Tulsidas Sitaram More

Nigrogi Venkata Ramakrishna

Greta Moraes

Anil Ghate

Jacqueline Trivedi

Vitthal G Gund

Mandakini Bipin Alreja

Ravishankar Vasumathy

Sadagopan Raghavan

Ashok K Gangopadbya

Shrikant V Rao

Subramani N Iyer

Subramani N Iver

Dipak C Chatterjee

Samina A Dohadwalla

Anis S Dohadwalla

Rashida A Dohadwalla

Deceased AliHussein Dohadwalla

Rajeshwari Kannan

The present invention relates to novel compounds for the inhibition of cyclin-dependent kinases, and more particularly, to chromenone derivatives of formula (Ia), wherein R, R, R, R, R, R, Rand A have the meanings indicated in the claims. The invention also relates to processes for the preparation of the compounds of formula (Ia), to methods of inhibiting cyclin-dependent kinases and of inhibiting cell proliferation, to the use of the compounds of formula (Ia) in the treatment and prophylaxis of diseases, which can be treated or prevented by the inhibition of cyclin-dependent kinases such as cancer, to the use of the compounds of formula (Ia) in the preparation of medicaments to be applied in such diseases. The invention further relates to compositions containing a compound of formula (Ia) either alone or in combination with another active agent, in admixture or otherwise in association with an inert carrier, in particular pharmaceutical compositions containing a compound of formula (Ia) either alone or in combination with another active agent, together with pharmaceutically acceptable carrier substances and auxiliary substances.

Inhibitors of cyclin dependent kinases and their use

The invention provides a novel benzoxazepine compound of the general formula (I): wherein Rand Rare as defined in the specification; or a stereoisomer, a geometric isomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, or a polymorph thereof; a process for its preparation; and a pharmaceutical composition including an effective amount of the compound. The compounds are useful in the treatment of insulin resistance and clinical conditions associated therewith.

Benzoxazepine compounds, their preparation and use

Guanidine derivatives having a condensed tricyclic ring of formula 1: are disclosed, wherein U is C(O), CRR, O, NRor S(O); V is CRRor NR; W is S(O); wherein Ris H, alkyl, cycloalkyl, alkenyl or aralkyl; Ris H, alkyl, OH, ORor OCOR, and m is the integer 0, 1 or 2; R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein with the proviso that at least one of R1, R2, R3, R4, R5, R6, R7 or R8 is guanidino or guanidinocarbonyl. These derivatives are sodium-proton exchange inhibitors and are useful as medicaments for the treatment of, for example, organ disorders associated with ischemia and reperfusion, cardiac arrhythmia, cardiac hypertrophy, hypertension, cell proliferative disorders and diabetes.

Tricyclic guanidine derivatives as sodium-proton exchange inhibitors

Compounds of formula 1: are disclosed, wherein V is CH; W is S(O); m is the integer 0, 1 or 2; U is O, C(O), CRRor NR; where Ris H, alkyl; Ris H, OH, ORor OCOR; Ris H, alkyl, cycloalkyl, alkenyl, C(O)R, C(O)ORor alkylaminocarbonyl; R, R, R, R, R, R, Rand Rare as defined herein. These compounds are inhibitors of tumor necrosis factor-alpha (TNF-&#x3b1;) and are useful as medicaments for the treatment and prevention of disorders caused by increased TNF-&#x3b1; activity, in particular inflammations.

Fused tricyclic compounds as inhibitors of tumor necrosis factor-alpha

This invention relates to novel fused bicyclic compounds of the general formula (I): wherein

Fibrinogen receptor antagonists and their use

Fused tricyclic compounds as inhibitors of tumor necrosis factor-&#x3b1;

The present invention relates to novel compounds for the inhibition of cyclin-dependent kinases, and more particularly, to chromenone derivatives of formula (Ic) wherein R, R, R, R, R, R, Rand A have the meanings indicated in the claims. The invention also relates to processes for the preparation of the compounds of formula (Ia), to methods of inhibiting cyclin-dependent kinases and of inhibiting cell proliferation, to the use of the compounds of formula (Ic) in the treatment and prophylaxis of diseases, which can be treated or prevented by the inhibition of cyclin-dependent kinases such as cancer, to the use of the compounds of formula (Ic) in the preparation of medicaments to be applied in such diseases. The invention further relates to compositions containing a compound of formula (Ic) either alone or in combination with another active agent, in admixture or otherwise in association with an inert carrier, in particular pharmaceutical compositions containing a compound of formula (Ic) either alone or in combination with another active agent, together with pharmaceutically acceptable carrier substances and auxiliary substances.

Guanidine derivatives having a condensed tricyclic ring of formula 1: are disclosed, wherein U is C(O), CRR, O, NRor S(O); V is CRRor NR; W is S(O); wherein Ris H, alkyl, cycloalkyl, alkenyl or aralkyl; Ris H, alkyl, OH, ORor OCOR, and m is the integer 0, 1 or 2; R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein with the proviso that at least one of R1, R2, R3, R4, R5, R6, R7 or R8 is guanidino or guanidino carbonyl. These derivatives are sodium-proton exchange inhibitors and are useful as medicaments for the treatment of, for example, organ disorders associated with ischemia and reperfusion, cardiac arrhythmia, cardiac hypertrophy, hypertension, cell proliferative disorders and diabetes.

This invention relates to novel fused bicyclic compounds of the general formula (I): whereinthe symbols are defined herein, to pharmaceutical compositions containing the compounds, processes for preparing the compounds, and to methods of using the compounds, alone or in combination with other therapeutic agents. The compounds are antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex, and are therefore useful for the inhibition of platelet aggregation, and for the treatment of thrombotic diseases and other diseases.

Inhibitors of cyclin-dependent kinases and their use

A cyclohexapeptide compound of general formula (I), wherein Ris C&#x2013;Calkyl; C&#x2013;Calkenyl; C&#x2013;Calkoxyphenyl; an aryl group selected from: phenyl, biphenyl, terphenyl and naphthyl; C&#x2013;Calkylphenyl, C&#x2013;Calkenylphenyl, C&#x2013;Calkoxyphenyl; linoleoyl; palmitoyl; 12-methylmyristoyl; 10,12-dimethylmyristoyl; or &#x2014;COCH(p)OCH, Rand Rare independently &#x2014;OH; &#x2014;CN; &#x2014;CHNH; &#x2014;N; aryl; substituted aryl; heterocyclyl and substituted heterocyclic with 1&#x2013;3 of the same or different heteroatoms; aminoalkylamino; mono or di-substituted linear or cyclic aminoalkylamino; &#x2014;OR, wherein, R is C&#x2013;Calkyl; substituted alkyl of the type &#x2014;(CH)&#x2014;X, where n is 1&#x2013;5 and X is Cl, Br, I, COOY, CN, NHor a heterocyclic and where Y is C&#x2013;Clinear or branched alkyl; C&#x2013;C-alkenyl; aryl; fused aryl; substituted aryl; a heterocyclic containing 1&#x2013;3 heteroatoms; mono or di-substituted aminoalkyl; or a hydroxy protecting group; and Rmay additionally be imidazolyl; Rand Rare independently &#x2014;H or &#x2014;OH; Ris &#x2014;H or &#x2014;CH, Ris &#x2014;H, &#x2014;CHor &#x2014;CHCONH. Ris &#x2014;H, &#x2014;CHor &#x2014;OH. Rand Rare independently &#x2014;H or &#x2014;CH-Sec.amine in which the sec.amine is attached to &#x2014;CHthrough its N linkage; and its pharmaceutically acceptable salts. The compounds are useful as antifungal agents.

Cyclohexapeptide compounds, processes for their production and their use as a pharmaceutical

Substituted 1-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic , and medicament containing them

Compounds of formula I, ##STR1## and the physiologically tolerable salts thereof, wherein the substituents R.sub.1 -R.sub.4 have the meanings given in the specifications and show an activity against inflammatory conditions.

Arylcycloalkyl derivatives, their production and their use

Growing community of inventors

Bombay, India

Bansi Lal